Pharmafile Logo

News and Press Releases

Rockville-Based CRO Emmes Groups’ OptymEdge launch the first dedicated ophthalmology clinical trial platform at ARVO

Phase 1 will see new eSource technology launched at event, marking OptymEdge’s evolution into a full-service ophthalmic research partner 14 May 2025 -- Wisconsin, US -- OptymEdge – part of...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 14, 2025

OptymEdge
11414 West Park Place, Suite 202, Milwaukee, WI 53224, US

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

1 May 2025 -- London, UK and New York, US -- OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 1, 2025

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

CSL Behring and GKV-Spitzenverband Agree on Reimbursement Price for HEMGENIX® – Europe’s First Gene Therapy for Haemophilia B

2 April 2025 -- Marburg, Germany -- CSL Behring and the GKV-Spitzenverband (National Association of Statutory Health Insurance Funds) have successfully concluded negotiations on the reimbursement price of HEMGENIX. This...

Category: Other, Pharmaceutical
Posted: April 2, 2025

CSL
CSL Global Headquarters, 655 Elizabeth Street, Melbourne VIC 3000 Australia

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

24 March 2025 -- California, US and Suzhou, China -- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025

Innovent
pr@innoventbio.com
1 Kingdom Street, Suite 445-446, London, W2 6BD, United Kingdom

Fondazione Telethon Submits US Biological License Application for Etuvetidigene Autotemcel Gene Therapy for the Treatment of Wiskott-Aldrich Sydrome

11 March 2025 -- Milan, Italy -- Fondazione Telethon, an Italian biomedical charity focused on rare genetic diseases, announced that it has submitted the Biologics License Application (BLA) for the...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 11, 2025

Fondazione Telethon
info@telethon.it
Via Poerio 14 - 20129 Milano

Boehringer Ingelheim and partners start clinical development of a first-in-class, inhaled gene therapy for people with cystic fibrosis

Ingelheim, Germany – Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931,...

Category: Biotechnology
Posted: February 24, 2025

Boehringer Ingelheim
Binger Strasse 173 55216 Ingelheim am Rhein

PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy

14 January 2025 -- Paris, France -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has submitted a Clinical...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 14, 2025

PulseSight Therapeutics
contact@pulsesight.com
PariSanté Campus, 2-10 Rue d’Oradour-sur-Glane, 75015 Paris

SEKISUI Completes £15.7 Million Expansion in cGMP Biopharma CDMO Capacity

Growth of UK facility will enable clinical-grade manufacturing of drug substances for range of biopharmaceutical products 14 November 2024 – Burlington, MA, USA – SEKISUI Diagnostics’ microbial CDMO business announces...

Category: Manufacturing and Packing
Posted: November 19, 2024

SEKISUI Diagnostics

ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

License agreement provides Université de Montréal access to CRISPR gene editing technology for use across its platform services 1 October 2024 -- Dublin, Ireland, and Montreal, Canada -- ERS Genomics...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: October 1, 2024

ERS Genomics
8th Floor, Block E, Iveagh Court, Harcourt Road, Dublin D02 YT22, Ireland

Exonate appoints Dr Rafiq Hasan as Non-Executive Director

Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board 28 May 2024 -- Cambridgeshire, UK -- Exonate, a biotechnology company developing...

Category: Biotechnology, Pharmaceutical
Posted: May 28, 2024

Exonate
info@exonate.com
WTL Moorfield Rd Duxford Cambridgeshire CB22 4PS United Kingdom